Bourne J T, Raynor W J, Verrier Jones J
Clin Exp Immunol. 1983 Jan;51(1):69-76.
We have attempted to demonstrate saturation of the mononuclear phagocyte system (MPS) in the Long Evans rat following intravenous administration of increasing doses of soluble HSA--125I-anti-HSA complexes. The fate of large (greater than 11S) complexes was followed by sucrose density gradient ultracentrifugation of serial serum samples in rats receiving 0.005-0.16 mg anti-HSA/g body weight. Administration of complexes provoked a rapid and profound increase in vascular permeability. Under these conditions no steady state clearance velocity for greater than 11S complexes could be established. The quantity of greater than 11S complexes removed from the circulation in the 1st hr never became independent of the initial dose. Specific immune complex uptake by the liver reached a maximum in rats receiving 0.09 mg anti-HSA/g body weight. Above this dose specific uptake decreased. Clearance of a tracer dose of complexes in rats pre-loaded with complexes containing 0.06 mg anti-HSA/g body weight was delayed for more than 3 hr. This was cautiously interpreted to indicate the period required for MPS recovery. The pattern of immune complex clearance in the context of marked changes in vascular permeability raised the possibility that maximum uptake was determined not by saturation of the mononuclear phagocyte system but by impaired hepatic perfusion.
我们试图通过静脉注射递增剂量的可溶性人血清白蛋白-125I-抗人血清白蛋白复合物,来证明Long Evans大鼠单核吞噬细胞系统(MPS)的饱和情况。在接受0.005-0.16mg抗人血清白蛋白/克体重的大鼠中,通过对系列血清样本进行蔗糖密度梯度超速离心,追踪大的(大于11S)复合物的命运。复合物的注射引起血管通透性迅速且显著增加。在这些条件下,无法确定大于11S复合物的稳态清除速度。在第1小时内从循环中清除的大于11S复合物的量从未与初始剂量无关。肝脏对特异性免疫复合物的摄取在接受0.09mg抗人血清白蛋白/克体重的大鼠中达到最大值。高于此剂量,特异性摄取量下降。预先注射含0.06mg抗人血清白蛋白/克体重复合物的大鼠中,示踪剂量复合物的清除延迟超过3小时。这被谨慎地解释为表明MPS恢复所需的时间。在血管通透性发生显著变化的情况下,免疫复合物的清除模式增加了一种可能性,即最大摄取量不是由单核吞噬细胞系统的饱和决定的,而是由肝脏灌注受损决定的。